Tome Skincare

Tome Biosciences is a biotechnology company pioneering programmable genomic integration (PGI) to develop a new generation of cell and gene therapies. By utilizing a proprietary platform that combines CRISPR-based targeting with site-specific integrases, the company can insert large DNA sequences into the genome with high precision and efficiency. Tome is initially focused on curative treatments for monogenic liver diseases and the development of cell therapies for B-cell mediated autoimmune conditions. The company emerged from stealth in late 2023 with over $200 million in funding to advance its pipeline toward clinical entry.